Sequent Scientific reported a net profit of Rs 3.4 crore for the quarter ending December 31, 2024, marking a significant 58.5% drop compared to Rs 8.2 crore in Q3 FY24. Despite this, the company witnessed growth in its top-line performance and margins.
Key Financial Highlights (YoY):
- Revenue: Increased by 18.7% to Rs 390.8 crore from Rs 329.3 crore in Q3 FY24.
- EBITDA: Jumped 56% to Rs 34.6 crore from Rs 22.2 crore.
- EBITDA Margin: Improved to 8.9% from 6.7% in the year-ago quarter.
- Net Profit: Declined to Rs 3.4 crore from Rs 8.2 crore, reflecting a hit to profitability.
The revenue boost was accompanied by improvements in operating margins; however, higher costs or other factors led to a decline in net profitability. The company’s performance remains under close watch by investors for sustained recovery.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
